Unsere aktuellen Studien

Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC)patients by deep phenotyping.

Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized phase III trial of the German Rectal Cancer Study Group

Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk, HR+/HER2- early breast cancer (ADAPTcycle)

A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with apecitabine or without capecitabine in adjuvant situation for biliary tract cancer

Postoperative adjuvant radiochemotherapy (aRCH) with Cisplatin (C) versus aRCH with C and Pembrolizumab (P) in locally advanced head and neck squamous cell carcinoma (HNSCC); multicenter randomized Phase II study within the German interdisciplinary study group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk

A phase II single-arm, open-label study of atezolizumab and derazantinib for patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements - ADVANCE

A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha-or Beta-Thalassemia (ENERGIZE-T)

International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients A randomized phase III trial of the German Rectal Cancer Study Group

International cooperative study for children and adolescents with standard risk anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine.